Description
Compounds are tested in a suitably standardised automated manner to collect quantitative data on their bioactivities by using a wide range of read-out technologies such as absorbance, luminescence, fluorescence or AlphaScreen and by implementing cell-based and biochemical assays. This high-throughput screening process allows researchers to rapidly identify compounds that modulate specific proteins or pathways of interest.

Service provider
Chemical Screening Unit and Medicinal Chemistry group,
Leibniz-Institute for Molecular Pharmacology 

Location
Berlin, Germany

Contacts
Scientific contact: Jens-Peter von Kries (high-throughput screening, bioactivity profiling),
                             Marc Nazaré (hit optimisation, labeling)
Technical contact: Jens-Peter von Kries,
                             Marc Nazaré